TUCSON, Ariz.--(BUSINESS WIRE)--HTG Molecular Diagnostics, a provider of molecular technology solutions, today announced, SR One, the corporate venture capital arm of GlaxoSmithKline, joined the second tranche of its series D financing. The company has raised $16.2 million in this series D financing. SR One joins this round which was led by Novo A/S and includes Fletcher Spaght Ventures, Merck Capital Ventures, Solstice Capital and Valley Ventures. Simeon George, Partner, SR One is joining HTG’s Board of Directors.
